Alcobra Ends Development Of MDX For Adult ADHD, Ponders Strategic Direction
Executive Summary
Failing to meet the primary endpoint in its second Phase III study in adult ADHD, the Israeli firm confirms there is no path forward in that indication. Developing MDX for Fragile X syndrome and business development options are under consideration.
You may also be interested in...
Arcturus Founder Reinstated As CEO As Settlement Ends Four-Month Feud With Former Board
The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.
Arcturus Enters Reverse-Merger With Alcobra To Push Differentiated RNA Approach
One company’s disappointment is another’s opportunity, as Arcturus will go public by merging with troubled Alcobra. The combined company will have seven preclinical programs, four run by partners.
Pharma's First Quarter: Approvals, Successes and Setbacks
As public companies prepare to present their financial reports for the first quarter of 2017, Scrip has gathered the stats on drug approvals for the first three months, as well as highlights of the biggest trial success and most disappointing clinical setbacks of this year so far.